Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 380

1.

Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.

Vakkilainen J, Mero N, Schweizer A, Foley JE, Taskinen MR.

Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):484-90.

PMID:
12469362
2.

Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

J Clin Pharm Ther. 2009 Feb;34(1):13-23. doi: 10.1111/j.1365-2710.2008.00984.x.

PMID:
19125899
3.
4.
5.

No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.

Johanson EH, Jansson PA, Gustafson B, Sandqvist M, Taskinen MR, Smith U, Axelsen M.

Diabetes Metab Res Rev. 2005 Jul-Aug;21(4):376-81.

PMID:
15724236
6.
7.

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.

Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE.

Diabetes Care. 2001 Jun;24(6):983-8.

PMID:
11375357
8.

Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.

Tentolouris N, Boutati E, Karambakalis N, Perrea D, Tselepis AD, Tsoukala C, Kyriaki D, Lourida E, Anastasopoulou I, Karafoullidou A, Raptis SA, Katsilambros N.

Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):6-12. Erratum in: Nutr Metab Cardiovasc Dis. 2006 Jan;16(1):81. Perea, D [corrected to Perrea, D].

PMID:
15871845
9.
10.

Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.

Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Cicero AF.

Intern Med. 2007;46(22):1837-46. Epub 2007 Nov 16.

12.

Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.

Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE.

Diabetes Care. 2003 Jun;26(6):1685-90.

PMID:
12766094
14.

Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

Diabetes Care. 2002 Dec;25(12):2147-52.

PMID:
12453952
15.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
16.

Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels.

Skrapari I, Perrea D, Ioannidis I, Karabina SA, Elisaf M, Tselepis AD, Karagiannacos P, Katsilambros N.

Diabet Med. 2001 Oct;18(10):781-5.

PMID:
11678967
17.

Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes.

Onishi Y, Fujisawa T, Sakaguchi K, Maeda M.

Adv Ther. 2006 Jul-Aug;23(4):549-55.

PMID:
17050498
18.

Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.

Gao HW, Xie C, Wang HN, Lin YJ, Hong TP.

Acta Pharmacol Sin. 2007 Apr;28(4):534-9.

19.

Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.

Voytovich MH, Haukereid C, Hjelmesaeth J, Hartmann A, Løvik A, Jenssen T.

Clin Transplant. 2007 Mar-Apr;21(2):246-51.

PMID:
17425753
20.

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

Campbell IW.

Int J Clin Pract. 2005 Oct;59(10):1218-28. Review.

PMID:
16178991
Items per page

Supplemental Content

Write to the Help Desk